For the twelve months ended Sep 30, 2026, Orchestra BioMed Holdings Inc. reported $31.21M of revenue and -$56.95M of net income.
OBIO revenueQ3 2026$91.0K
- Quarter YoY
- -89.4%
- QoQ
- +3.4%
- FY YoY
- 13x
OBIO revenue was $91.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 89.4% from a year earlier and up 3.4% from the prior quarter. For the full fiscal 2025 it was $33.48M, up about 13-fold from fiscal 2024. It rose in 1 of the last 3 fiscal years.
OBIO net incomeQ3 2026-$18.75M
OBIO net income was -$18.75M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$20.83M a year earlier. For the full fiscal 2025 it was -$52.70M, compared with -$61.02M in fiscal 2024.
OBIO EPSQ3 2026-$0.30
OBIO diluted EPS was -$0.30 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.40 a year earlier. For the full fiscal 2025 it was -$1.11, compared with -$1.66 in fiscal 2024.
OBIO free cash flowQ3 2026-$19.94M
OBIO free cash flow was -$19.94M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.86M a year earlier. For the full fiscal 2025 it was -$49.45M, compared with -$50.85M in fiscal 2024.
Source: XBRL data Orchestra BioMed Holdings Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.